Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 581 across all filing types
Latest filing 2026-06-09 Proxy Solicitation & In…
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS: Notice of General Assembly - Attachment: Softox Solutions AS AGM 24 June 2026.pdf
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal notice convening the Annual General Meeting of Softox Solutions AS, with agenda items, resolutions, proxy and attendance forms, and voting instructions. It is a solicitation of proxies and information statement sent to shareholders to request votes for the meeting, rather than the meeting’s presentation materials (AGM-R) or the actual annual report. Thus it fits the Proxy Solicitation & Information Statement category.
2026-06-09 English
SoftOx Solutions AS: Notice of General Assembly
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a “Notice of General Assembly” outlining the date, agenda and board proposals for an upcoming shareholder meeting and directing shareholders to informational materials. This is a proxy solicitation/information communication to request votes and inform shareholders ahead of the meeting, matching the Proxy Solicitation & Information Statement category (PSI).
2026-06-09 English
SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
Share Issue/Capital Change Classification · 92% confidence The document is a company announcement that the board has resolved a private placement of new shares (share issuance), specifying the subscription price, number of shares issued, new share capital, waiver of preferential rights, and related details. This constitutes a share issue/capital change event rather than a full financial report, management commentary, or regulatory filing. Therefore, it is classified as Share Issue/Capital Change (SHA).
2026-06-09 English
SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE - Attachment: Press Release Dose Escalation.pdf
Regulatory Filings Classification · 92% confidence The document is a press release announcing the completion of a Phase 2a dose-escalation clinical trial and the initiation of a proof-of-concept patient phase for SoftOx Solutions AS’s SIS-03 program. It does not contain financial statements or results, nor does it pertain to board changes, dividends, regulatory forms like 10-K or 6-K, proxy materials, or M&A activity. It is a general corporate announcement of operational news. No other specialized category fits, so it falls into Regulatory Filings (RNS) as a catch-all for miscellaneous corporate announcements.
2026-06-08 English
SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE
Regulatory Filings Classification · 76% confidence The document is a corporate press release announcing the completion of the dose-escalation phase and the initiation of a proof-of-concept phase for a clinical trial (SIS-03) by SoftOx Solutions AS. It provides operational/technical trial progress, not an annual or interim financial report, earnings release, M&A, or governance material. It is a regulatory disclosure under section 5-12 of the Norwegian Securities Trading Act, fitting the definition of a general regulatory announcement or miscellaneous regulatory filing. Therefore, it is classified as Regulatory Filings (RNS).
2026-06-08 English
SoftOx Solutions AS: FIRST PARTICIPANT ENROLLED IN BIODEFENCE-FOCUSED SIS-02 PHASE 1 CLINICAL STUDY - Attachment: Press Release FSFV SIS-02 (1).pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the enrollment of the first participant in a Phase 1 clinical study, not a financial report or a detailed regulatory form. It does not fit any specific filing type like earnings release, interim report, or M&A activity. It is a public regulatory announcement under disclosure requirements, making it a general regulatory filing (RNS).
2026-06-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.